Figure 3. Number of large clones is of prognostic importance.

3a) Number of clones >0.5% repertoire at day 21 is significantly greater in responding patients than in control samples (clones identified by TRA chain, n=25 controls, 49 patients, two-sided Wilcoxon signed-rank Test, lower and upper hinge of box on boxplots represent 25-75^th percentiles, central line the median and the whiskers extend to largest and smallest values no greater than 1.5x interquartile range); 3b) replication cohort (n=43 controls, 20 patients, one-sided Wilcoxon signed-rank Test, boxplot as per 3a); 3c) Day 21 large clone count associates with 6 month outcomes after sICB (left panel, n=42), cICB (centre panel, n=27), when considering all ICB (right panel, n=69, P values all one-sided Wilcoxon-signed rank Test, boxplot as per 3a); 3d) Shorter progression-free survival in patients with day 21 large clone count below median versus those with count above (P=0.003, two-sided Log-rank test, n=69); 3e) Kaplan-Meier survival curve demonstrates reduced overall survival in patients with day 21 large clone count below median versus those with count above (P=0.01, two-sided Log-rank test, n=69); 3f) correlation between large clone count and cell subset percentages from flow cytometry (72 samples, 19 patients, r reflects Pearson correlation, P value obtained from two-sided T-statistic).